T1 |
Discovery to candidate health application |
Observational studies; Phases I and II clinical trials |
Development of an accurate test for the FOA gene, based on the discovery of an association between the FOA gene and obesity; early testing of genetically based interventions for feasibility and safety |
T2 |
Health application to evidence-based practice guidelines |
Observational studies; Phase III clinical trials; evidence synthesis and guidelines development |
What is the positive predictive value of FOA mutations in at-risk populations? What are the effects of obesity-reduction interventions in persons with and without risk-conferring mutations? |
T3 |
Practice guidelines to health practice |
Dissemination research; implementation research; diffusion research; Phase IV cinical trials |
Whet proportion of population who met the family history criteria is tested for the FOA gene; are there barriers to testing? What approaches can improve the delivery of effective personalized genetically based approaches in clinical practice settings? |
T4 |
Practice to population health impact |
Outcomes research (includes many disciplines); population monitoring of morbidity, mortality, benefits, and risk |
Does FOA testing in normal and overweight individuals reduce incidence for obesity or improve outcome? Does delivery of genetically targeted interventions improve public-health outcomes? |